Analysts’ Recent Ratings Changes for Neurocrine Biosciences (NBIX)

Neurocrine Biosciences (NASDAQ: NBIX) has recently received a number of price target changes and ratings updates:

• 12/29/2025 – Neurocrine Biosciences was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 12/17/2025 – Neurocrine Biosciences had its price target raised by analysts at HC Wainwright from $168.00 to $198.00. They now have a “buy” rating on the stock.
• 12/12/2025 – Neurocrine Biosciences had its price target raised by analysts at Mizuho from $146.00 to $175.00. They now have a “neutral” rating on the stock.
• 12/11/2025 – Neurocrine Biosciences had its price target raised by analysts at Stifel Nicolaus from $183.00 to $188.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Neurocrine Biosciences had its price target raised by analysts at Royal Bank Of Canada from $160.00 to $180.00. They now have an “outperform” rating on the stock.
• 12/5/2025 – Neurocrine Biosciences had its price target raised by analysts at TD Cowen from $175.00 to $200.00. They now have a “buy” rating on the stock.
• 11/11/2025 – Neurocrine Biosciences had its price target lowered by analysts at Morgan Stanley from $178.00 to $173.00. They now have an “overweight” rating on the stock.
• 11/3/2025 – Neurocrine Biosciences had its price target raised by analysts at JPMorgan Chase & Co. from $171.00 to $179.00. They now have an “overweight” rating on the stock.

Insider Buying and Selling at Neurocrine Biosciences

In other news, Director Leslie V. Norwalk sold 1,190 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total value of $184,557.10. Following the transaction, the director directly owned 6,239 shares of the company’s stock, valued at $967,606.51. This trade represents a 16.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Kyle Gano sold 300 shares of the firm’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $141.97, for a total transaction of $42,591.00. Following the completion of the transaction, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at $19,933,581.79. This represents a 0.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 43,866 shares of company stock valued at $6,570,237. Corporate insiders own 4.80% of the company’s stock.

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.